[1] |
GUO Longxin, GAO Yunjuan, WU Chengzhao, LONG Minjuan, ZHU Shengkai, SONG Haibo, ZHAO Xu, XIAO Xiaohe.
Exploring new risk signals and susceptibility factors of traditional Chinese medicine-induced hepatotoxicity based on big data from adverse reaction monitoring
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 15-19.
|
[2] |
YANG Yan, ZHOU Dexi, WU Xinli, XUE Shuya, DING Haihua, ZHANG Quan, ZHANG Yunling.
Eighty-four cases of adverse drug reactions caused by novel anti-tumor drugs
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 334-338.
|
[3] |
YAO Xin, GE Qiuge, LI Yamin, WANG Yifan, LI Yuanyuan, LIU Zhiqiang.
Adverse drug reactions caused by new anti-tumor drugs from 2018 to 2022 in one hospital
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1273-1278.
|
[4] |
DONG Shoutang, ZHANG Xuqiang, WANG huaibin, CHAI Lianzhou, YANG Hongqin, HU Yan.
Antioxidant effect of Dendrobium devonianum polysaccharides on oxidative damage mice induced by D-galactose
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1078-1081.
|
[5] |
WANG Xiao, HE Xuan, DAI Huizhen, LI Xin, HAN Feng.
Market Competition Trends of Innovative Anti-tumor Drugs in Nanjing Based on Terminal Data
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(8): 731-736.
|
[6] |
WANG Yanchun, WANG Jianqiang.
Research Progress in Clinical Application of Shuganning Injection
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(8): 543-547.
|
[7] |
WANG Tao.
Mechanism and Safety Risk of Anti-novel Coronavirus Pneumonia Drug-tocilizumab
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(5): 257-260.
|
[8] |
LI Sizheng, HU Guang, HE Jingcheng, HU Yuchi, LI Zhiyong, JIN Hongtao.
The Role of Renin-angiotensin System in COVID-19 and Drug Intervention
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(5): 267-271.
|
[9] |
QIU Caixia, YANG Cuiping, JIN Hongtao.
Research Progress in Mechanisms of Drug-induced Kidney Injury
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(11): 688-694.
|
[10] |
LI En-can, HE Jiu-ming, JIN Hong-tao, LIN Ni.
Research Progress of Pharmacological Activity and Toxicity of 5-Hydroxymethylfurfural
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(4): 210-215.
|
[11] |
WANG Shuo, CHEN Naihong, YUAN Yuhe.
Advances in Research on Targeted Treatment of Alzheimer's Disease
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(12): 755-760.
|
[12] |
FENG Hong-yun, FAN Yan, WU Gui-zhi, DONG Duo.
Analysis of the Perception of Risk on Drug-induced Progressive Multifocal Leukoencephalopathy
[J]. Chinese Journal of Pharmacovigilance, 2016, 13(9): 557-562.
|
[13] |
FENG Hong-yun, FAN Yan, WU Gui-zhi, DONG Duo.
Research of the Risk Factors and Practice of Drug Risk Management on Drug-induced Progressive Multifocal Leukoencephalopathy
[J]. Chinese Journal of Pharmacovigilance, 2016, 13(8): 472-475.
|
[14] |
SHI Liang,SUN Rong.
Advances in Establishment of Animal Models with Hepatic Cirrhosis and Thinking about Efficacy Evaluation of Traditional Chinese Medicine
[J]. Chinese Journal of Pharmacovigilance, 2016, 13(1): 32-35.
|
[15] |
TIAN Yi, YANG Yue, TIAN Li-juan.
Progress and Implication of FDA Risk Communication in the United States
[J]. Chinese Journal of Pharmacovigilance, 2016, 13(1): 24-27.
|